{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bone+Scan&page=21", "query": { "intervention": "Bone Scan", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 548, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bone+Scan&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bone+Scan&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T09:36:13.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06922318", "title": "The COSMYC Trial (COmbined Suppression of MYC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "ZEN-3694", "type": "DRUG" }, { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) analogue", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2025-08-19", "completion_date": "2031-08-30", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06922318" }, { "nct_id": "NCT06179888", "title": "Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Skeletal Survey X-Ray", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2024-08-27", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 74, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 55 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179888" }, { "nct_id": "NCT04301076", "title": "Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Adult T-Cell Leukemia/Lymphoma", "Adult T-Cell Leukemia/Lymphoma", "Chronic Adult T-Cell Leukemia/Lymphoma", "HTLV-1 Infection" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-08-31", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 19, "location_summary": "Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "City of Saint Peters", "state": "Missouri" }, { "city": "Creve Coeur", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04301076" }, { "nct_id": "NCT07758673", "title": "Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent B Lymphoblastic Lymphoma", "Refractory B Acute Lymphoblastic Leukemia", "Refractory B Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Autologous BAFFR-targeting CAR T Cells", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bridge Therapy", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Ultrasonographic Elastography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2027-04-17", "completion_date": "2028-07-26", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07758673" }, { "nct_id": "NCT02436356", "title": "New Tools for Assessing Fracture Risk", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Osteoporosis", "Fracture Risk Assessment" ], "interventions": [ { "name": "Osteoprobe-Reference Point Indentation (RPI)", "type": "DEVICE" }, { "name": "Dual-energy X-ray absorptiometry (DXA) Scans", "type": "RADIATION" }, { "name": "MRI", "type": "RADIATION" } ], "intervention_types": [ "DEVICE", "RADIATION" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2015-06-30", "completion_date": "2018-11-08", "has_results": true, "last_update_posted_date": "2020-11-02", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02436356" }, { "nct_id": "NCT01886105", "title": "Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Osteosarcoma" ], "interventions": [ { "name": "Sm-EDTMP", "type": "DRUG" }, { "name": "Autologous Stem Cell Infusion", "type": "OTHER" }, { "name": "External Beam Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "10 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2013-08-19", "completion_date": "2017-06-11", "has_results": true, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01886105" }, { "nct_id": "NCT01585402", "title": "Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arterial Calcification", "CD73 Deficiency" ], "interventions": [ { "name": "Etidronate", "type": "DRUG" }, { "name": "MRI Scan", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 7, "start_date": "2012-08-20", "completion_date": "2021-08-06", "has_results": true, "last_update_posted_date": "2022-10-04", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585402" }, { "nct_id": "NCT07468916", "title": "Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified", "Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ropeginterferon Alfa-2B", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2026-09-29", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07468916" }, { "nct_id": "NCT04946552", "title": "Sympathetic Activation in Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Healthy" ], "interventions": [ { "name": "PET Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Mixed Meal Test", "type": "DIETARY_SUPPLEMENT" }, { "name": "Muscle sympathetic nerve activity (MSNA)", "type": "DIAGNOSTIC_TEST" }, { "name": "Oral Glucose Tolerance Test", "type": "DIAGNOSTIC_TEST" }, { "name": "Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)", "type": "OTHER" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 5, "start_date": "2021-11-23", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2024-02-16", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04946552" }, { "nct_id": "NCT02115425", "title": "Calibrate Samsung's BIA to Meseaure Body Composition", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Body Composition", "Circumference Measurements", "Tissue Thickness Measurements" ], "interventions": [ { "name": "Body Measurements", "type": "OTHER" }, { "name": "Whole Body DXA Scan", "type": "OTHER" }, { "name": "Bioelectrical Impedance Analysis (BIA)", "type": "OTHER" }, { "name": "add name here", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Pennington Biomedical Research Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "10 Years to 80 Years" }, "enrollment_count": 421, "start_date": "2014-04", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-09-29", "last_synced_at": "2026-10-18T09:36:13.337Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115425" } ] }